The Cystic Fibrosis Foundation is accepting Letters of Intent for its Therapeutics Development Award Program.
By supporting early to mid-phase drug development activities with both financial and technical support, the Cystic Fibrosis Foundation’s Therapeutics Development Award (TDA) program is designed to stimulate and de-risk CF drug development of novel therapies for cystic fibrosis. The program provides companies with funding and other resources in support of studies that may include drug discovery, pre-clinical safety, pharmacokinetics/pharmacodynamics (PK/PD), and clinical studies in people with CF through Phase 2 development. Awards will be made for either discovery or preclinical and initial clinical development activities (all therapeutic areas relevant to CF).
Applications will be considered in any therapeutic area that could benefit people with CF but are particularly encouraged in areas related to treating CF infections, CFTR modulation, mucus clearance (mucolytics and airway surface hydration), inflammation, chronic lung allograft dysfunction, CF-related diabetes, CF liver disease, and nutrition.
The TDA program provides two mechanisms of support:
Component I Awards: Funds up to $600,000 over two years will be awarded for early exploratory, discovery, and/or preclinical development studies.
Component II Awards: Considered for more advanced programs that generally have identified a clinical candidate and are moving into investigational new drug (IND)-enabling studies such as PK/PD, GLP toxicology, and Phase 1/2 clinical trials in CF patients. Component II awards are typically supported at a level of up to $3 million to $5 million for two or more years and require substantial matching funds. Only direct costs are covered.
Both U.S.-based and non-U.S. based (i.e., international) companies engaged in research and development are invited to apply.